Annual Report

Overview

The report describes a challenging 2025, with Group operating revenue of RMB2,446.31 million, down 8.71% year on year. It also highlights multiple product approvals and continued clinical and registration progress across ophthalmology, medical aesthetics and orthopedics. The company completed the privatization and delisting of EndyMed, making it a wholly-owned subsidiary. Sustainability and ESG matters are assigned to the Board's Strategy and Sustainable Development Committee.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 20 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services